Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
43 hedge funds and large institutions have $4.17M invested in Eiger BioPharmaceuticals, Inc. in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 13 closing their positions.
16% less funds holding
Funds holding: 51 → 43 (-8)
32% less capital invested
Capital invested by funds: $6.08M → $4.17M (-$1.92M)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$101K |
| 2 |
HF
HRT Financial
New York
|
+$8.54K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$6.28K |
| 4 |
Jane Street
New York
|
+$4.33K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$3.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$824K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$319K |
| 3 |
6CM
683 Capital Management
New York
|
-$161K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$120K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$109K |
EIGR Hedge Fund Activity: Q4 2023 in Review
43 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2023, worth a combined $4.17M — down 32% from $6.08M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of EIGR and 5 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $101K. The largest seller was Simplify Asset Management, exiting entirely with an estimated $824K sold.
- 43 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2023, down from 51 in Q3 2023.
- Funds reported $4.17M of Eiger BioPharmaceuticals, Inc. stock for Q4 2023, down 32% quarter-over-quarter.
- 5 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2023 and 13 closed out, a net change of -8 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2023 was Renaissance Technologies, an estimated $101K added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2023 was Simplify Asset Management, an estimated $824K sold.
Based on aggregated 13F filings for Q4 2023.